Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $14.5595, but opened at $16.54. Ono Pharmaceutical shares last traded at $16.54, with a volume of 108 shares trading hands.
Analyst Ratings Changes
Separately, Zacks Research raised Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Ono Pharmaceutical has a consensus rating of “Strong Buy”.
Get Our Latest Stock Analysis on OPHLF
Ono Pharmaceutical Stock Up 13.6%
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.
One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.
Read More
- Five stocks we like better than Ono Pharmaceutical
- Strategic Strike: Strategy Deploys $370M to Fortify Bitcoin
- Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
- From High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend Payouts
- The Pentagon’s Grok Rollout Puts These 3 Stocks in Focus
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
